Skip to main content
Click here to get access to our Free Course on Momentum Investing Strategy

NSE · VALIANTLAB

VALIANTLAB

HealthcarePharmaceuticals & Biotechnology₹561 cr market cap
₹96.84 ▼ -1.99% today As of 19 Nov 2026
52-week low ₹50.9352-week high ₹140.75

-29.8% from the 52-week high · +94.0% above the low

Valiant Laboratories Ltd manufactures pharmaceuticals, chemicals, and healthcare products. The company serves hospitals, clinics, and industrial clients with quality-driven manufacturing and regulatory compliance.

The short version. VALIANTLAB reported revenue of ₹117 crore for Sep 2026, up 154.3% from a year earlier. Return on equity was -1.1% in Mar 2026. Promoter holding was 74.94% in Sep 2026, up 0.00 points over 8 quarters.

1 · The price

How has the stock traded?

VALIANTLAB trades 29.8% below its 52-week high and 94.0% above its 52-week low.

Change over period: —

1M-29.8%
3M+7.4%
6M+29.1%
1Y+24.4%

2 · The business

Is it growing?

Sales, year on year+154.3%

Sep 2026 revenue of ₹117 cr.

Net margin0.4%

Unchanged from a year earlier.

Reported results · ₹ crore

Revenue and profit

Show the numbers

Quarterly

Sep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue117115925246475835
Net profit0212-70212
Net margin %0.418.31.9-13.50.43.91.26.7
EPS (₹)0.083.890.32-1.30.040.340.130.43

Annual

FY2026FY2025FY2024
Revenue237133182
Net profit-3-20
Net margin %-1.4-1.70.2
EPS (₹)-0.6-0.410.06

3 · The quality

How well does it turn capital into profit?

Return on equity was -1.1% in Mar 2026; debt to equity is 0.14.

Profitability · 3 years

Returns and margins

Mar 2026Mar 2025Mar 2024
Return on equity %-1.1-0.90.1
Return on capital %0.8-0.4-0.2
EBITDA margin %3.60.50.7
Net margin %-1.4-1.60.2

Compound growth

Revenue vs profit

3 years5 years
Revenue CAGR——
Profit CAGR——
Debt to equity0.14
Interest cover1.4x
Current ratio1.91
P/E ratio34.2

4 · The owners

Who holds it, and are they adding?

Promoter holding74.94%

Unchanged over 8 quarters.

Foreign institutions0.07%

Up 0.07 pts over 8 quarters.

Domestic institutions0.08%

Up 0.08 pts over 8 quarters.

Mutual fund schemes0

+0 versus the previous month.

Shareholding pattern (%)

Quarter by quarter

Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026Change
Promoter74.9474.9474.9474.9474.9474.9474.9474.940.0
FII00.640.630.020.010.200.07+0.07
DII000.4600000.08+0.08
Public25.0624.4223.9725.0425.0524.8625.0624.91-0.15

5 · The model view

What does our factor model say?

Factor scores, model flags and screen results for VALIANTLAB are part of the Wright portfolio review.

Run your free portfolio review

Watchouts

What to review

Model flags are shown inside the portfolio review, alongside your other holdings.

Model ratingLocked
Factor betaLocked
VolatilityLocked

Quick answers

Common questions about VALIANTLAB

What is the VALIANTLAB share price?

VALIANTLAB (VALIANTLAB) last closed at ₹96.84, down 1.99% on the day. Its 52-week range is ₹50.93 to ₹140.75.

What is the market cap of VALIANTLAB?

VALIANTLAB has a market capitalisation of about ₹561 crore. Its price-to-earnings ratio is 34.2.

How are VALIANTLAB's latest results?

VALIANTLAB reported revenue of ₹117 crore for Sep 2026, up 154.3% from a year earlier. Return on equity was -1.1% in Mar 2026. Promoter holding was 74.94% in Sep 2026, up 0.00 points over 8 quarters.

Who owns VALIANTLAB?

As of Sep 2026, shareholding was: Promoter 74.94%, FII 0.07%, DII 0.08%, Public 24.91%.

How many mutual funds hold VALIANTLAB?

0 mutual fund schemes held VALIANTLAB in October 2026. That compares with 0 the month before.

Corporate actions

Recent dividends, bonuses and splits

  • 18 Jul 2025 · Rights issue 1:4

Financials are as reported by the company (consolidated), in ₹ crore. Source: FinEdge exchange filings feed. Figures can differ from other sites because of one-off items and restatements. Callouts above are arithmetic on reported data, not recommendations.

Research data on this page is provided under Wright Research's SEBI Research Analyst registration. The Terms & Conditions of our Research Analyst services apply.